TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with Crohn's Disease~* Previous treatment failure to Infliximab (intolerance and/or no response)~Exclusion Criteria:~* Obstructive intestinal strictures~* Recent bowel resection~* Proctocolectomy or total colectomy~* Current total parenteral nutrition~* Short bowel syndrome~* All concomitant diseases or pathological conditions that could interfere with Crohn's disease assessment or to be harmful for the well being of the patient~* Previous clinical trials and previous biological therapy that could interfere with the results in the present clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active 1 (Type: EXPERIMENTAL): Q4W regimen~- every 4 weeks: alternatively placebo and 400mg Certolizumab Pegol
- Active 2 (Type: EXPERIMENTAL): Q2W regimen~- every 2 weeks: 400 mg Certolizumab Pegol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D3 Treatment and Homocysteine Concentrations Among Overweight Reproductive Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Overweight (BMI between 25-29.99 kg/m2)~* Had 25(OH)D \< 20 ng/mL~* Had normal vitamin B-12 and folic acid levels~* Not diagnosed with any chronic diseases~* Agreed to participat in the study~Exclusion Criteria:~* age \< 18 or \> 49 years~* BMI \> 30 kg/m2 or \< 25 kg/m2~* 25 (OH)D level \> 20 ng/ml~* tHcy levels greater than 100 µmol/L~* Abnormal vitamin B-12 or folic acid levels~* Chronic diseases~* Pregnant or lactating

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- vitamin D3 (Type: ACTIVE_COMPARATOR): 50,000 IU
- Placebo (Type: PLACEBO_COMPARATOR): Similar in size, shape and color to vitamin D3

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessing the Efficacy of IV Ibuprofen for Treatment of Pain in Orthopedic Trauma Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Trauma patient admitted to Trauma ICU or Trauma Step-Down Units.~2. Fracture of ribs, face, extremities and/or pelvis~3. Age between 18 and 75 years old~4. Adequate IV access~5. Able to self report and communicate pain severity~Exclusion Criteria:~1. History of allergy or hypersensitivity to any component of IV Ibuprofen, aspirin (or aspirin related products) NSAIDs, or COX-2 inhibitors~2. Any intracranial or spinal cord trauma~3. History of clinically significant bleeding disorders including ITP, DIC or platelet dysfunction~4. Recent history of intracranial surgery or stroke (within past 30 days)~5. History of ulcers, gastritis or previous GI bleeding~6. Renal Impairment (Creatinine \> 3.0 mg/dL)~7. Pregnant or breastfeeding~8. Otherwise unsuitable in the opinion of the treating physician at time of randomization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- IV Ibuprofen 800 mg (Type: ACTIVE_COMPARATOR): IV Ibuprofen 800 mg
- IV Saline (Type: PLACEBO_COMPARATOR): IV Saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Topical Radial Artery Vasodilation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Undergoing trans-radial cardiac catheterization~Exclusion Criteria:~* inability to receive nitroglycerin or lidocaine due to allergy or medication interactions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Topical dilator (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Supported Education Pilot

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* PTSD~* OIF/OEF Service~Exclusion Criteria:~None

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Supported Education (Type: EXPERIMENTAL): Veterans received supported education services. A Veteran peer met weekly as needed with a subject for up to six months in a psycho-social rehabilitation service for meeting education goals. Goals included choosing a college, getting admitted or enrolled, and maintaining enrollment and completing classes.
- General Peer Support (Type: ACTIVE_COMPARATOR): Matched attention was provided by a Veteran peer who met weekly with Veterans but who focused on help with any personal goal (eg, employment, housing) but not on education.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1/2A, Single Dose Study Of PF-04383119 In Japanese Patients With Moderate To Severe Pain From Osteoarthritis Of The Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese Male or female, Age 35-65 (Part 1), Age 35-75 (Part 2)~* Diagnosis of osteoarthritis (OA) of the knee based on American College of Rheumatology criteria~* Knee pain, and radiographic evidence of knee OA (Kellgren-Lawrence x-ray grade ≥2) obtained within 1 year of enrollment~* At least one of the following: age \>50, morning stiffness \<30 minutes in duration, crepitus, and OA of the knee must involve the index tibiofemoral joint and must have present for at least 6 months~* Patients who meet at least one of the following: unwilling to take non-opiate pain medications, or for whom non-opiate pain medications have failed, or are candidates for or seeking invasive interventions such as intraarticular injections, knee arthroplasty, or total knee surgery~* Pain levels as required by the protocol at Screening and Baseline~Exclusion Criteria:~* Diagnosis or history of RA, any inflammatory arthritis, gout, Paget's disease or any other disease that in the Investigator's opinion would interfere with the assessment of pain and other symptoms of OA~* Patients with regional pain syndromes suggestive of fibromyalgia or regional pain caused by lumbar or cervical compressions with radiculopathy or at risk of developing radiculopathy.~* Diagnosis or history of fibromyalgia~* Planned surgical procedure during the duration of the study

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 10 mcg/kg (Type: EXPERIMENTAL): None
- 100 mcg/kg (Type: EXPERIMENTAL): None
- 200 mcg/kg (Type: EXPERIMENTAL): None
- 25 mcg/kg (Type: EXPERIMENTAL): None
- 50 mcg/kg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug in Healthy Postmenopausal Females

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal female, age at least 45 years at the time of signing informed consent. With at least 12 consecutive months since the last spontaneous menstrual bleeding (if there was any uncertainty of the time of the last spontaneous bleeding, the postmenopausal status is to be confirmed with follicle stimulating hormone (FSH) 40 mIU/mL)~* Body mass index (BMI) between 20.0 and 29.9 kg/m\^2 (both inclusive)~* Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator~Exclusion Criteria:~* Smoker (defined as a subject who is smoking at least one cigarette or the equivalent per day). A subject smoking less than one cigarette or the equivalent per day must be able or willing to refrain from smoking and use of nicotine substitute products during the trial~* Any blood draw in excess of 25 mL in the past 30 days, or donation of blood or plasma in excess of 400 mL within the 90 days preceding screening~* Sitting blood pressure at screening (after resting for at least 5 minutes) outside the range of 90-139 mmHg for systolic or 50-89 mmHg for diastolic. If white-coat hypertension is suspected a single repeat measurement is allowed, last measurement being conclusive~* History of major surgical procedures involving the stomach potentially affecting absorption of trial product (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery)

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Oral contraceptive/SNAC/Oral Trial drug (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 years~* Medical record documentation of CDAD either: a) at least two recurrences after a primary episode and have completed at least two rounds of standard-of-care oral antibiotic therapy or b) have had at least two episodes of severe CDAD resulting in hospitalization.~* Willing and able to have an enema(s).~* Already taking or will start a course of oral antibiotics for CDAD symptoms for 10-14 days, including at least seven days of oral vancomycin.~* Willing and able to complete the required subject diary.~Exclusion Criteria:~* Continued (uncontrolled) CDAD after completing a 10-14 day course of oral antibiotics.~* Requires antibiotic therapy for a condition other than CDAD.~* Previous fecal transplant prior to study enrollment.~* History of inflammatory bowel disease (IBD), e.g., ulcerative colitis, Crohn's disease, or microscopic colitis.~* History of irritable bowel syndrome (IBS).~* History of chronic diarrhea.~* History of celiac disease.~* History of cirrhosis of the liver or ascites.~* Disease symptoms caused by a confirmed intestinal pathogen other than Clostridium difficile.~* Has a colostomy.~* Intraabdominal surgery within the last 60 days.~* Evidence of active, severe colitis.~* History of short gut syndrome or motility disorders.~* Requires the regular use of medications that affect bowel motility (e.g., metoclopramide, narcotics, loperamide).~* Planned therapy in the next 3 months that may cause diarrhea (e.g., chemotherapy).~* Planned surgery requiring perioperative antibiotics within 6 months of study enrollment.~* Life expectancy of \< 12 months.~* Compromised immune system, e.g., HIV infection (any CD4 count); AIDS-defining diagnosis or CD4 \<200/mm3; inherited/primary immune disorders; immunodeficient or immunosuppressed due to a medical condition or medication; current or recent (\< 90 days) treatment with chemotherapy; or current or recent (\< 90 days) treatment with immunosuppressant medications.~* Taking steroids (≥ 20 mg a day) or is expected to be on steroids for more than 30 days after enrollment.~* Neutropenia (white blood cell count \<1000 cells/µL).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RBX2660 (microbiota suspension) (Type: EXPERIMENTAL): enema-based delivery of RBX2660

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study in Patients With Erectile Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* History of Erectile Dysfunction (ED) of at least 3 months duration.~* Anticipate having the same adult female sexual partner during the study.~* Agree not to use any other treatment for ED and to participate in recording responses to questionnaires and other instruments used in this study.~Exclusion Criteria:~* Previous or current treatment with tadalafil or any other phosphodiesterase type 5 (PDE5) inhibitor.~* ED caused by other primary sexual disorders, history of radical prostatectomy or other pelvic surgery with subsequent failure to achieve any erection, or history of penile implant or clinically significant penile deformity.~* ED caused by untreated or inadequately treated endocrine disease.~* Current treatment with doxazosin, nitrates, cancer chemotherapy, or anti-androgens.~* Severe renal or hepatic impairment, history of malignant hypertension.~* Presence or history of specific heart conditions.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tadalafil on demand (Type: EXPERIMENTAL): 10 milligrams (mg) or 20 mg on demand
- Tadalafil once a day (Type: EXPERIMENTAL): 5 mg or 2.5 mg once a day
- Sildenafil Citrate (Type: ACTIVE_COMPARATOR): 50 mg, 100 mg, or 25 mg on demand

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase IIa, Randomized, Double Blinded, Placebo Controlled, Dose Finding Study for TLC599 in OA Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Main Inclusion Criteria:~1. Male or female patients, at least 50 years of age.~2. Documented diagnosis of OA of the knee for at least 6 months~3. The study knee has OA with Grade 2 to 3 severity based on the Kellgren Lawrence grades~4. Patients with patient related visual analogue scale (VAS) score of 5.0 to 9.0 at baseline.~5. Willing and able to comply with study procedures and provide written informed consent.~Main Exclusion Criteria:~1. Patients who received systemic corticosteroids within the last 30 days prior to dosing.~2. Patients who use prohibited medications within 7 days prior to study drug administration or any pain control medication including acetaminophen within 48 hours prior to study drug administration.~3. Patients who use prohibited medications other than acetaminophen and oral NSAIDs from screening visit to 7 days prior to study drug administration.~4. Documented history and confirmed autoimmune disease~5. History of post-traumatic knee arthritis, or evidence of intra articular bleeding of the study knee~6. History of infective arthritis~7. Unstable study knee joint~8. Use of IA corticosteroid, hyaluronic acid, or other IA injection in the study knee within 3 months prior to the screening visit.~9. A history of treated malignancy which is disease free for ≤ 5 years prior to the screening visit~10. Uncontrolled and unstable concurrent medical or psychiatric illness, that will jeopardize the safety of the patient~11. Use of any chemotherapeutic or systemic immunosuppressant agents for inflammatory diseases within 6 months prior to the screening visit.~12. Current use of anticoagulants, including warfarin, heparin, low molecular weight heparin, or dabigatran.~13. Abnormalities of laboratory parameters as described below will qualify for exclusion:~    * hemoglobin \< 8 g/dL;~   * total white blood cell count \< 4000/ µL;~   * serum bilirubin/ alanine aminotransferase/ aspartate aminotransferase \> 2 times upper limit of normal (ULN) for the laboratory reference ranges;~   * serum creatinine \> 2 times ULN for the laboratory reference range;~   * serum uric acid \> ULN for the laboratory reference range;~   * prothrombin time/International Normalized Ratio \> ULN for the laboratory reference range.~14. Contraindication to undergoing magnetic resonance imaging (MRI)

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TLC599 LD group (Type: EXPERIMENTAL): 12 mg DSP with 100 µmol PL (1.0 mL)
- TLC599 HD group (Type: EXPERIMENTAL): 18 mg DSP with 150 µmol PL (1.5 mL)
- Placebo group (Type: PLACEBO_COMPARATOR): 1.5 mL normal saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Effects of YisuiShengxueGranules on Thalassemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Intermedia α-Thalassemia; intermedia β-Thalassemia; severe β-Thalassemia.~2. Syndrome of Deficiency of Liver-yin and Kidney-yin, and Asthenia of Essence and Blood.~3. Male or female, 3-40 years of age.~4. Provision of written informed consent.~Exclusion Criteria:~1. Complications with critical illness such as cerebrovascular disease, cardiovascular disease, hepatic disease, renal disease, malignancy and etc.~2. Allergy to any ingredients of Yisui Shengxue Granules~3. Psychiatric disorder.~4. Blood transfusion in the latest 90 days for severe β-Thalassemia; blood transfusion in the latest 45 days for intermediaβ-Thalassemia or intermedia α-Thalassemia.。~5. Upper respiratory tract infection with temperature higher than 38.5℃ in the latest 45 days.~6. Taking other antianemic agents in the latest 2 months.~7. Participation in any other clinical interventional trial in the latest 1 month.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- research (Type: None): biological research on the effects of yisuishengxuegranule
- clinical research (Type: None): clinical research on thalassemia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed ICF (Informed Consent Form)~* Subject-reported history of Drye Eye Disease (DED) in both eyes~* Ability and willingness to follow instructions, including participation in all study assessments and visits~Exclusion Criteria:~* Women who are pregnant, nursing or planning pregnancy~* Unwillingness to submit a blood pregnancy test at screening and the last visit (or early termination visit) if of childbearing potential, or unwillingness to use acceptable means of birth control~* Clinically significant slit-lamp findings or abnormal lid anatomy at screening~* Ocular/peri-ocular malignancy~* History of herpetic keratitis~* Active ocular allergies or ocular allergies that are expected to be active during the study~* Ongoing ocular or systemic infection~* Wear contact lenses within 1 month prior to screening or anticipated use of contact lenses during the study~* Intra-ocular surgery or ocular laser surgery within the previous 6 months, or have planned ocular and/or lid surgeries over the study period~* Presence of uncontrolled systemic diseases~* Presence of known allergy and/or sensitivity to the study drug or saline components~* Use of any topical steroids treatments, topical cyclosporine, lifitegrast, serum tears or topical anti-glaucoma medication within 2 months prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NOV03 4 times daily (QID) (Type: EXPERIMENTAL): 100% Perfluorohexyloctance solution 4 times daily (QID)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete